Announcements Trials
Browse Landscape

Phase

Phase 2 49Phase NA 25Phase 1 17Phase 1/2 11Phase 3 6Phase 2/3 4Phase EARLY_PHASE1 2Phase 4 1

Status

Unknown 10Terminated 8Completed 7Recruiting 6Not yet recruiting 2Active not recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 6

Conditions

Breast Neoplasms 129Carcinoma, Non-Small-Cell Lung 101Prostatic Neoplasms 62Colorectal Neoplasms 49Nasopharyngeal Carcinoma 45Neoplasms 44Multiple Myeloma 42Stomach Neoplasms 35Neoplasm Metastasis 32Leukemia, Myeloid, Acute 32Ovarian Neoplasms 31Lung Neoplasms 31Carcinoma, Hepatocellular 29Squamous Cell Carcinoma of Head and Neck 27Rectal Neoplasms 27Pancreatic Neoplasms 26Triple Negative Breast Neoplasms 25Recurrence 25Small Cell Lung Carcinoma 21Brain Neoplasms 21Esophageal Neoplasms 20Colonic Neoplasms 20Uterine Cervical Neoplasms 19Lymphoma, Large B-Cell, Diffuse 17Head and Neck Neoplasms 17Urinary Bladder Neoplasms 16Leukemia, Lymphocytic, Chronic, B-Cell 16Esophageal Squamous Cell Carcinoma 16Carcinoma, Renal Cell 16Myasthenia Gravis 15

Interventions

Oxaliplatin 2Gemcitabine 2Cisplatin 2zanidatamab 1toripalimab 1pembrolizumab 1lenvatinib 1ivosidenib 1durvalumab 1Tissue Adhesives 1Pancreaticojejunostomy 1Leucovorin 1Irinotecan 1Injections 1Folfox protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × Recruiting × Cholangiocarcinoma × Clear all
NCT07265674 2026-05-14

Beacon-BTC

J-Pharma Co., Ltd.

Phase 3 Recruiting
480 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06282575 2026-05-11

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Jazz Pharmaceuticals

Phase 3 Recruiting
286 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT05876754 2026-02-19

ProvIDHe

Servier

Phase 3 Recruiting
220 enrolled
Gastrointestinal

Cholangiocarcinoma

NCT07155525 2025-09-18

NBCA-MS

Minia University

Phase 3 Recruiting
194 enrolled
Gastrointestinal

Bile Duct Neoplasms, Duodenal Neoplasms, Pancreatic Neoplasms, Cholangiocarcinoma

NCT05342194 2025-04-23

Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study

Shanghai Junshi Bioscience Co., Ltd.

Phase 3 Recruiting
480 enrolled
Gastrointestinal

Cholangiocarcinoma

NCT05948475 2024-06-24

FIRST-308

TransThera Sciences (Nanjing), Inc.

Phase 3 Recruiting
200 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡